ERBB3 and cancer: To ascertain whether different expression of NRG1 by CAFs translates into variable activation of the HER3 pathway in cancer cells, we stimulated T47D and MCF7 cancer cells with conditioned media (CM) from the isolated CAFs, and used lumretuzumab to block ligand–receptor binding.